Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Evaluating Aggressive B Cell Lymphomas

Leuk Lymphoma; ePub 2017 Sep 3; Raess, et al

Publish date:: September 13, 2017

Conducting complete immunohistochemical (IHC) and FISH analysis is likely the best way to evaluate aggressive B cell lymphomas (ABCLs), concluded researchers after conducting a study involving 187 individuals. Participants had ABCL, which investigators evaluated using complete IHC and FISH analysis. Among the results:

Morphologic and IHC analysis could not identify clinically relevant high-grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
~Three-fourths of these cases showed conventional diffuse large B-cell lymphoma morphologic features.
14% of MYC-rearranged cases were negative by IHC.
Conversely, 60% of cases positive for MYC by IHC did not demonstrate a MYC rearrangement.
Analysis by FISH without MYC and BCL2 IHC would have missed 41 cases of double expressor lymphoma.

Citation:

Raess P, Moore S, Cascio M, et al. MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes. [Published online ahead of print September 3, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1370547.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in Lymphoma & Plasma Cell Disorders

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Outcomes Post-AlloSCT in DHL/DEL Lymphomas, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Anthracycline-Related CV Dysfunction Evaluated, Cancer; ePub 2017 Nov 7; Armenian, Mertens, et al

Adcetris Approved for Primary Cutaneous ALCL, FDA news release; 2017 Nov 9